GlobeNewswire Inc | Aug 4, 2020 07:30AM EDT

August 04, 2020

CELEBRATION, Fla., Aug. 04, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast onWednesday, August 12, 2020, at 4:30 p.m. ET, to discuss its corporate and financial results for the second quarter 2020.

Conference Call Information:

Interested participants and investors may access the conference call by dialing either:

-- (866) 395-2480 (U.S.) -- (678) 509-7538 (international) -- Conference ID: 5176398

An audio webcast with slide presentation will be accessible via the Investor Relations section of the Companys website, http://investors.kempharm.com/. An archive of the webcast and presentation will be available for 90 days beginning at approximately5:30 p.m. ET, onAugust 12, 2020.

About KemPharm:

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LATTM (Ligand Activated Therapy) technology.KemPharm utilizes its proprietary LATTM technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharms co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook and YouTube.

KemPharm Contacts:Jason Rando / Maureen McEnroeTiberend Strategic Advisors, Inc.212-375-2665 / 2664jrando@tiberend.commmcenroe@tiberend.com